Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.12 (-1.12%) Market Cap: 616.66 Mil Enterprise Value: -40.99 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit (Virtual) Transcript

Jul 13, 2021 / 06:25PM GMT
Release Date Price: €44.31 (-1.95%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Hi, everyone. Thanks for joining us this afternoon for the Sage fireside chat here at Cowen's first Annual Neuropsychiatry Summit. I'm covering analyst, Ritu Baral. And joining us from Sage is CEO, Barry Greene, and long-standing CMO, Steve Kanes, who most of you know.

So thanks, everyone, for joining us. E-mail me any questions as we go along or submit them in the chat.

Questions & Answers

Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

I guess zuranolone is going to be the main focus of this conference. We've been focused on depression and PTSD all day. Steve, can you -- just as a reminder, sort of briefly take us through zuranolone mechanism. And I think we've all heard this, but one of the biggest criticisms of the mechanism and especially in terms of your most recent data was, from the investor side, how is this mechanism not just in benzo. So as you take us through the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot